• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·US·Healthcare·ABSI
Share

Absci Corporation Stocks

$ 6.08Last Updated 28.05.2026

Issuer Rating

2/7
Performance

Modest

Risk

High

Recommendation

Sell

Market Cap

$ 815.01M

$ 6.08
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Favourable analyst view

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Latest news

29.05.2026 16:52

BTIG initiates on Absci as leader of 'GLP-1 moment for hair loss'; stock jumps 18%

10.03.2026 19:24

Three AI small caps that look ready to extend gains as investors grow more selective

31.10.2025 13:00

A rising tide lifts all boats: How tech small caps gained from the AI boom in 3Q25

03.10.2025 15:21

New York morning: shutdown vs. statistics - investors left without key data

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.

Company Valuation

Greatly overvalued
1/7

Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers.

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Favourable
6/7

The average target price of ABSI is 8.4 and suggests 38% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

30.05.2026 03:57

One of the most popular cryptocurrencies in the world is entering the US market

30.05.2026 03:28

Barclays expects a turnaround in lagging sectors. Which stocks are likely to win?

30.05.2026 02:40

Kazakhstan can accept Iranian uranium reserves - IAEA head

30.05.2026 01:28

U.S. stocks posted their ninth consecutive week of gains. This has not happened in three years

30.05.2026 00:56

Space stocks collapse after Blue Origin rocket explosion and SpaceX valuation drop

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn
  • X (Twitter)
  • LinkedIn
Oninvest© 2026